Want to see CRVO full AI Analyst Report?
Top Page
CervoMed
(NASDAQ:CRVO)
Select Model
Select Model
Rating:46Neutral
Price Target:
$2.50
▼(-5.66% Downside)
Action:Reiterated
Date:10/13/26
The score is held down primarily by weak financial performance (minimal revenue, large losses, and heavy cash burn) and a broadly bearish price trend versus key moving averages. Positive corporate events around neflamapimod development and regulatory progress partially offset these risks, but the negative P/E and lack of dividend support keep valuation from contributing meaningfully.
Positive Factors
Clinical biomarker progress
The Phase 2a biomarker signal provides evidence that neflamapimod may affect a marker of neuronal degeneration in a rare dementia population. If supported by the trial’s later controlled period, this could strengthen the lead program’s clinical rationale and broader development potential.
Negative Factors
Minimal commercial revenue
The very small revenue base shows that CervoMed has not yet reached meaningful commercial scale, while the large net loss reflects substantial development spending. Until a product generates material revenue, earnings remain highly dependent on clinical progress and future financing.
Read all positive and negative factors
Positive Factors
Negative Factors
Clinical biomarker progress
The Phase 2a biomarker signal provides evidence that neflamapimod may affect a marker of neuronal degeneration in a rare dementia population. If supported by the trial’s later controlled period, this could strengthen the lead program’s clinical rationale and broader development potential.
Read all positive factors
CervoMed (CRVO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$33.41M
Dividend YieldN/A
Average Volume (3M)252.74K
Price to Earnings (P/E)―
Beta (1Y)-0.52
Revenue Growth-95.74%
EPS Growth-23.18%
CountryUS
Employees15
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-3.21
Shares Outstanding15,119,096
10 Day Avg. Volume207,305
30 Day Avg. Volume252,740
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)3.92
Price to Sales (P/S)0.00
P/FCF Ratio-3.05
Enterprise Value/Market Cap0.20
Enterprise Value/Revenue21.14
Enterprise Value/Gross Profit21.14
Enterprise Value/Ebitda-0.22
Forecast
1Y Price Target
$15.50Price Target Upside484.91% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-2.15
Revenue Forecast (FY)$133.33K
CervoMed Business Overview & Revenue Model
Company Description
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that cro...
CervoMed Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
48
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 322.57K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 322.57K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -30.35M | -26.97M | -16.29M | -2.17M | -5.80M | -15.94M |
| Net Income | -30.35M | -26.97M | -16.29M | -2.17M | -5.80M | -24.10M |
Balance Sheet | ||||||
| Total Assets | 25.99M | 23.40M | 43.08M | 9.97M | 4.16M | 37.84M |
| Cash, Cash Equivalents and Short-Term Investments | 24.94M | 20.86M | 38.92M | 7.79M | 4.09M | 37.31M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 12.41M | 0.00 |
| Total Liabilities | 3.03M | 5.18M | 3.88M | 2.60M | 13.16M | 2.93M |
| Stockholders Equity | 22.96M | 18.22M | 39.20M | 7.38M | -9.00M | 34.91M |
Cash Flow | ||||||
| Free Cash Flow | -27.98M | -23.45M | -16.53M | -7.45M | -2.57M | -14.50M |
| Operating Cash Flow | -27.98M | -23.45M | -16.53M | -7.45M | -2.57M | -14.50M |
| Investing Cash Flow | 23.19M | 18.10M | -28.66M | 0.00 | 0.00 | 4.00K |
| Financing Cash Flow | 18.93M | 4.59M | 46.40M | 11.15M | 0.00 | 33.30M |
CervoMed Technical Analysis
Negative
2.65
Price Trends
2.60
Negative
2.83
Negative
3.59
Negative
Market Momentum
-0.14
Positive
37.59
Neutral
33.89
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CRVO, the sentiment is Negative. The current price of 2.65 is above the 20-day moving average (MA) of 2.64, above the 50-day MA of 2.60, and below the 200-day MA of 3.59, indicating a bearish trend. The MACD of -0.14 indicates Positive momentum. The RSI at 37.59 is Neutral, neither overbought nor oversold. The STOCH value of 33.89 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CRVO.
CervoMed Risk Analysis
CervoMed disclosed 75 risk factors in its most recent earnings report. CervoMed reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
CervoMed Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $17.93M | -0.34 | -618.87% | ― | ― | 73.74% | |
46 Neutral | $33.41M | -0.69 | -156.02% | ― | -95.74% | -23.18% | |
45 Neutral | $330.39M | -5.24 | -75.35% | ― | 220.34% | 55.73% | |
44 Neutral | $332.14M | -2.79 | -63.05% | ― | -51.65% | 91.93% | |
42 Neutral | $29.10M | -3.70 | -71.47% | ― | -100.00% | -55.90% |
* Healthcare Sector Average
CRVO
CervoMed
2.21
-4.67
-67.88%
XFOR
X4 Pharmaceuticals
3.35
-0.39
-10.43%
ABVC
ABVC BioPharma
1.09
-1.68
-60.65%
JSPR
Jasper Therapeutics
0.54
-1.82
-77.20%
PRLD
Prelude Therapeutics
4.14
2.56
162.03%
ESLA
Estrella Immunopharma
0.82
-1.64
-66.63%
CervoMed Corporate Events
Business Operations and Strategy
CervoMed reports encouraging biomarker data in Phase 2a trial
Positive
Oct 13, 2026
On October 12, 2026, CervoMed reported initial 12-week biomarker data from the open-label portion of its Phase 2a trial of neflamapimod in nonfluent variant primary progressive aphasia, a rare frontotemporal dementia with no approved treatments in...
Business Operations and StrategyRegulatory Filings and Compliance
CervoMed Updates Investor Presentation and Disclosure Practices
Neutral
Oct 9, 2026
CervoMed announced that summary information on its business, clinical programs, development plans, and financial position is available in an investor presentation on its website under the events and presentations section. The company noted that th...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
CervoMed Advances Neflamapimod Tablet and Dosing Strategy
Positive
Sep 28, 2026
On September 28, 2026, CervoMed reported new pharmacokinetic, regulatory, and manufacturing advances for neflamapimod, including a 50 mg oral tablet that uses a more stable crystalline form and a controlled process intended to support consistent l...
Business Operations and Strategy
CervoMed highlights late-breaking neflamapimod Phase 2a data
Positive
Sep 10, 2026
On September 10, 2026, CervoMed announced that initial results from its Phase 2a trial of neflamapimod in nonfluent variant primary progressive aphasia have been accepted for a late-breaking oral presentation at the International Society of Fronto...
Business Operations and StrategyRegulatory Filings and Compliance
CervoMed’s neflamapimod gains UK Innovation Passport
Positive
Aug 4, 2026
On August 4, 2026, CervoMed announced that neflamapimod, its oral small-molecule drug targeting neuroinflammation in degenerative brain disorders, was granted an Innovation Passport under the United Kingdom’s Innovative Licensing and Access ...
Business Operations and Strategy
CervoMed advances neflamapimod strategy with new DLB data
Positive
Jul 15, 2026
On July 14, 2026, CervoMed reported new clinical, plasma biomarker and imaging data for neflamapimod in dementia with Lewy bodies at the Alzheimer’s Association International Conference in London, highlighting analyses from the 159-patient P...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.